Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Top Cited Papers
Open Access
- 7 December 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (12), e15004
- https://doi.org/10.1371/journal.pone.0015004
Abstract
The interrogation of proteomes (“proteomics”) in a highly multiplexed and efficient manner remains a coveted and challenging goal in biology and medicine. We present a new aptamer-based proteomic technology for biomarker discovery capable of simultaneously measuring thousands of proteins from small sample volumes (15 µL of serum or plasma). Our current assay measures 813 proteins with low limits of detection (1 pM median), 7 logs of overall dynamic range (∼100 fM–1 µM), and 5% median coefficient of variation. This technology is enabled by a new generation of aptamers that contain chemically modified nucleotides, which greatly expand the physicochemical diversity of the large randomized nucleic acid libraries from which the aptamers are selected. Proteins in complex matrices such as plasma are measured with a process that transforms a signature of protein concentrations into a corresponding signature of DNA aptamer concentrations, which is quantified on a DNA microarray. Our assay takes advantage of the dual nature of aptamers as both folded protein-binding entities with defined shapes and unique nucleotide sequences recognizable by specific hybridization probes. To demonstrate the utility of our proteomics biomarker discovery technology, we applied it to a clinical study of chronic kidney disease (CKD). We identified two well known CKD biomarkers as well as an additional 58 potential CKD biomarkers. These results demonstrate the potential utility of our technology to rapidly discover unique protein signatures characteristic of various disease states. We describe a versatile and powerful tool that allows large-scale comparison of proteome profiles among discrete populations. This unbiased and highly multiplexed search engine will enable the discovery of novel biomarkers in a manner that is unencumbered by our incomplete knowledge of biology, thereby helping to advance the next generation of evidence-based medicine.Keywords
This publication has 45 references indexed in Scilit:
- Unlocking Biomarker Discovery: Large Scale Application of Aptamer Proteomic Technology for Early Detection of Lung CancerPLOS ONE, 2010
- Biomarker discovery and clinical proteomicsTrAC Trends in Analytical Chemistry, 2009
- Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasmaNature Biotechnology, 2009
- A HUPO test sample study reveals common problems in mass spectrometry–based proteomicsNature Methods, 2009
- Mass Spectrometry Based Targeted Protein Quantification: Methods and ApplicationsJournal of Proteome Research, 2008
- Functional Aptamers and Aptazymes in Biotechnology, Diagnostics, and TherapyChemical Reviews, 2007
- Magnitude of Underascertainment of Impaired Kidney Function in Older Adults with Normal Serum CreatinineJournal of the American Geriatrics Society, 2007
- Engineering novel binding proteins from nonimmunoglobulin domainsNature Biotechnology, 2005
- A method for reducing the time required to match protein sequences with tandem mass spectraRapid Communications in Mass Spectrometry, 2003
- Empirical Statistical Model To Estimate the Accuracy of Peptide Identifications Made by MS/MS and Database SearchAnalytical Chemistry, 2002